UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Reduces Holdings in TG Therapeutics, Inc. (NASDAQ:TGTX)

UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC lessened its position in shares of TG Therapeutics, Inc. (NASDAQ:TGTX - Free Report) by 7.3% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 272,370 shares of the biopharmaceutical company's stock after selling 21,557 shares during the period. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC owned approximately 0.17% of TG Therapeutics worth $8,198,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors have also recently made changes to their positions in TGTX. Quadrant Capital Group LLC increased its holdings in shares of TG Therapeutics by 137.1% in the 4th quarter. Quadrant Capital Group LLC now owns 1,686 shares of the biopharmaceutical company's stock worth $51,000 after buying an additional 975 shares during the last quarter. Blue Trust Inc. increased its holdings in shares of TG Therapeutics by 24.5% in the 4th quarter. Blue Trust Inc. now owns 1,887 shares of the biopharmaceutical company's stock worth $57,000 after buying an additional 371 shares during the last quarter. Smartleaf Asset Management LLC increased its holdings in shares of TG Therapeutics by 512.5% in the 4th quarter. Smartleaf Asset Management LLC now owns 1,905 shares of the biopharmaceutical company's stock worth $60,000 after buying an additional 1,594 shares during the last quarter. Jones Financial Companies Lllp increased its holdings in shares of TG Therapeutics by 460.7% in the 4th quarter. Jones Financial Companies Lllp now owns 2,114 shares of the biopharmaceutical company's stock worth $64,000 after buying an additional 1,737 shares during the last quarter. Finally, 1620 Investment Advisors Inc. bought a new position in shares of TG Therapeutics in the 4th quarter worth $128,000. Institutional investors own 58.58% of the company's stock.

Analysts Set New Price Targets

TGTX has been the subject of a number of research reports. Wall Street Zen raised shares of TG Therapeutics from a "sell" rating to a "hold" rating in a research note on Tuesday, March 4th. HC Wainwright reaffirmed a "buy" rating and issued a $55.00 price objective on shares of TG Therapeutics in a research note on Tuesday, March 4th. Two research analysts have rated the stock with a hold rating and four have assigned a buy rating to the company's stock. Based on data from MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and an average price target of $40.80.

TG Therapeutics Trading Up 1.7%

Shares of TG Therapeutics stock traded up $0.62 during trading on Wednesday, reaching $37.03. The company's stock had a trading volume of 1,210,284 shares, compared to its average volume of 2,967,814. TG Therapeutics, Inc. has a 52-week low of $15.16 and a 52-week high of $46.48. The company has a market cap of $5.88 billion, a price-to-earnings ratio of -370.26 and a beta of 2.21. The firm's 50-day moving average is $37.17 and its two-hundred day moving average is $34.53. The company has a quick ratio of 3.91, a current ratio of 4.59 and a debt-to-equity ratio of 1.27.

TG Therapeutics (NASDAQ:TGTX - Get Free Report) last announced its quarterly earnings results on Wednesday, May 7th. The biopharmaceutical company reported $0.03 earnings per share for the quarter, missing the consensus estimate of $0.19 by ($0.16). The firm had revenue of $120.86 million for the quarter, compared to analysts' expectations of $117.07 million. TG Therapeutics had a negative net margin of 5.42% and a negative return on equity of 8.32%. The company's quarterly revenue was up 90.4% on a year-over-year basis. During the same period in the previous year, the company earned ($0.07) EPS. On average, sell-side analysts anticipate that TG Therapeutics, Inc. will post 0.08 earnings per share for the current year.

TG Therapeutics Profile

TG Therapeutics, Inc, a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults.